NASDAQ: ARWR · Biotechnology

Arrowhead Pharmaceuticals (ARWR) fair value and price range

As of 15 Nov 2026, Faircurve's model values Arrowhead Pharmaceuticals (ARWR) at $53.67 a share. The stock last closed at $44.21, which puts the model's fair value 21.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. Arrowhead Pharmaceuticals, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$53.67midpoint of 2,000 simulations
Last close$44.21NASDAQ: ARWR
Gap to fair value+21.4%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 15 Nov 2026 moved the fair value from $54.23 to $53.67 (-1.0%). The multiple the model anchors on moved, lowering the fair value: most of the move.

What the model makes of itThe price of $44.21 is 21.4% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 20% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ARWR?

The calibrated range for ARWR over 63 trading days is $35.37 to $55.88. It sits around the last close, and its width comes from the volatility that ARWR's own options imply (68% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $31.17 to $85.50. In 58% of the simulations the fair value came out above the price the model ran on.

$15.42$169.26
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $53.67. Dashed line: the last close, $44.21.

Faircurve Insights · 15 Nov 2026

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company based in Pasadena, California, founded in 1989. It works on innovative treatments for complex and challenging-to-treat diseases within the United States.

Faircurve's model valued Arrowhead Pharmaceuticals (ARWR) on 15 Nov 2026 and found a fair value of $53.67 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $54.23, so the model's fair value moved -1.0%. In the model's own words, "The multiple the model anchors on moved, lowering the fair value: most of the move." The calibrated range over 63 trading days runs from $38.62 to $59.74. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.

Arrowhead's overall quality score is 36 out of 100, a composite of six quality factors scored against comparable companies. Earnings quality scores 100. Stability scores 0, with EBITDA margin downside volatility at 5634.7 pts over five years. Growth quality scores 3, with trailing revenue growth at -45.6%. The model compares Arrowhead with Protagonist Therapeutics, Inc. (PTGX), TG Therapeutics, Inc. (TGTX) and BioMarin Pharmaceutical Inc. (BMRN), each with its own fair value on the site.

Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ARWR report earnings, and how has the stock reacted?

Arrowhead Pharmaceuticals's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 15.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ARWR's 30 day implied volatility works out to about 19.5% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ARWR's last 8 reports, ignoring direction, was 5.9%.

0%10%20%30%40%14.2%39.2%26 Nov '2411.0%6.7%10 Feb '2512.7%0.7%7 Aug '2521.5%30.4%25 Nov '2512.7%5.2%5 Feb '268.5%8.2%7 May '2617.1%1.0%4 Aug '269.0%3.2%12 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in ARWR

10%15%20%25%30%12 Nov '26 report4 Aug '26 report7 May '26 report5 Feb '26 report25 Nov '25 report20% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 25% on 14 Nov 2025, reached 25% on 14 Nov 2025 and reads 20% on 16 Nov 2026. The marks are report dates.

How does ARWR score on business quality?

Arrowhead Pharmaceuticals's overall quality score is 36 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.5-71.6%ROIC
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).100
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.3-45.6%Revenue growth, trailing
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.720.0%Net buybacks / market value
Balance sheetNet debt to EBITDA and interest coverage.70-1.49xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.05634.7 ptsEBITDA margin downside volatility, 5y

How does ARWR compare with similar companies?

The companies in biotechnology closest to Arrowhead Pharmaceuticals in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
LGND Ligand Pharmaceuticals Incorporated$301.71$282.99-6.2%Low evidence grade
CYTK Cytokinetics, Incorporated$53.17$63.03+18.5%Low evidence grade
PTGX Protagonist Therapeutics, Inc.$124.83$104.97-15.9%Overvalued
PTCT PTC Therapeutics, Inc.$60.97$74.62+22.4%Low evidence grade
KRYS Krystal Biotech, Inc.$297.90$352.42+18.3%Low evidence grade
TGTX TG Therapeutics, Inc.$62.76$75.36+20.1%Undervalued
BMRN BioMarin Pharmaceutical Inc.$57.99$69.09+19.1%Undervalued
HALO Halozyme Therapeutics, Inc.$96.50$111.93+16.0%Low evidence grade

What the comparable companies' multiples alone would give for ARWR, the peer-implied price, is $131.50 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Arrowhead Pharmaceuticals at a glance

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States.

Market value
$6.7B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$337M
Consensus revenue growth, next fiscal year
-32.1%
Analysts with estimates
12
Beta to the US market
1.27
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices Arrowhead Pharmaceuticals on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ARWR was $54.23. As of 15 Nov 2026 it is $53.67, a change of -1.0%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Arrowhead Pharmaceuticals's valuation

Is Arrowhead Pharmaceuticals stock undervalued or overvalued?

Faircurve's model puts ARWR's fair value at $53.67 a share against a last close of $44.21, as of 15 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is ARWR's fair value?

$53.67 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $31.17 to $85.50.

What price range does the model give ARWR?

$35.37 to $55.88 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Arrowhead Pharmaceuticals report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has ARWR moved on past earnings reports?

Across its last 8 reports the median two session move was 5.9%, ignoring direction. The largest was +39.2% around the report of 26 Nov 2024.

How confident is the model in this valuation?

The model's evidence grade for ARWR is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ARWR

The model holds no idea open on ARWR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ARWR with their outcomes. A free account is enough.

Keep reading